Suppr超能文献

TrkB 诱导 EMT,并在头颈部鳞状细胞癌的侵袭中起关键作用。

TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma.

机构信息

Department of Head and Neck Surgery, Houston TX, USA.

出版信息

Oncogene. 2010 Apr 8;29(14):2047-59. doi: 10.1038/onc.2009.486. Epub 2010 Jan 18.

Abstract

Head and neck squamous cell carcinoma (HNSCC) remains a significant public health problem, accounting for over 5% of all cancer-related deaths, and these deaths primarily result from metastatic disease. The molecular processes involved in HNSCC pathogenesis and progression are poorly understood, and here we present experimental evidence for a direct role of the cell surface receptor tyrosine kinase, TrkB, in HNSCC tumor progression. Using immunohistochemical analysis and transcriptional profiling of archival HNSCC tumor specimens, we found that TrkB and its secreted ligand, brain-derived neurotrophic factor (BDNF), are expresses in greater than 50% of human HNSCC tumors, but not in normal upper aerodigestive tract (UADT) epithelia. Studies with HNSCC cell lines reveal that in vitro stimulation with BDNF, the ligand for TrkB, upregulates the migration and invasion of HNSCC cells, and both transient and stable suppressions of TrkB result in significant abrogation of constitutive and ligand-mediated migration and invasion. Furthermore, enforced overexpression of TrkB results in altered expression of molecular mediators of epithelial-to-mesenchymal transition (EMT), including downregulation of E-cadherin and upregulation of Twist. Using an in vivo mouse model of HNSCC, we were able to show that downregulation of TrkB suppresses tumor growth. These results directly implicate TrkB in EMT and the invasive behavior of HNSCC, and correlate with the in vivo overexpression of TrkB in human HNSCC. Taken together, these data suggest that the TrkB receptor may be a critical component in the multi-step tumor progression of HNSCC, and may be an attractive target for much needed new therapies for this disease.

摘要

头颈部鳞状细胞癌(HNSCC)仍然是一个重大的公共卫生问题,占所有癌症相关死亡的 5%以上,这些死亡主要是由于转移性疾病。HNSCC 发病机制和进展中涉及的分子过程知之甚少,在这里我们提出了细胞表面受体酪氨酸激酶 TrkB 直接参与 HNSCC 肿瘤进展的实验证据。通过对存档的 HNSCC 肿瘤标本进行免疫组织化学分析和转录谱分析,我们发现 TrkB 及其分泌配体脑源性神经营养因子(BDNF)在超过 50%的人类 HNSCC 肿瘤中表达,但在上呼吸道(UADT)上皮中不表达。对 HNSCC 细胞系的研究表明,BDNF(TrkB 的配体)体外刺激可上调 HNSCC 细胞的迁移和侵袭,瞬时和稳定抑制 TrkB 可显著阻断固有和配体介导的迁移和侵袭。此外,强制过表达 TrkB 会导致上皮间质转化(EMT)的分子介质表达发生改变,包括 E-钙粘蛋白下调和 Twist 上调。通过 HNSCC 的体内小鼠模型,我们能够证明下调 TrkB 可抑制肿瘤生长。这些结果直接将 TrkB 牵连到 EMT 和 HNSCC 的侵袭行为中,并与人类 HNSCC 中 TrkB 的体内过表达相关。综上所述,这些数据表明 TrkB 受体可能是 HNSCC 多步肿瘤进展的关键组成部分,并且可能是这种疾病急需新疗法的有吸引力的靶点。

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验